SUMF1 - Sulfatase Modifying Factor 1

📖 Wiki Page

gene2144 wordssynced 2026-04-02

SUMF1 — Sulfatase Modifying Factor 1

Introduction

Sulfatase Modifying Factor 1 (SUMF1) is a crucial endoplasmic reticulum-localized enzyme that catalyzes the unique post-translational modification required for the catalytic activity of all sulfatases. The enzyme converts a conserved cysteine residue within sulfatase proteins to formylglycine (FGly), an essential modification that enables sulfatases to perform their hydrolytic functions["^1"]. This modification is fundamentally important because without it, all sulfatases remain catalytically inactive, leading to severe metabolic consequences.

...

SUMF1 — Sulfatase Modifying Factor 1

Introduction

Mermaid diagram (expand to render)

The gene encoding SUMF1 is located at chromosome 2q33.1 and has been extensively studied due to its critical role in sulfatase biology and its involvement in multiple sulfatase deficiency (MSD), a rare but devastating autosomal recessive disorder["^2"]. Recent research has also revealed intriguing connections between SUMF1 function and various aspects of neurodegenerative disease biology, particularly through its effects on lysosomal function, extracellular matrix remodeling, and cellular stress responses.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Sulfatase Modifying Factor 1</th></tr>
<tr><td>Gene Symbol</td><td>SUMF1</td></tr>
<tr><td>Full Name</td><td>Sulfatase Modifying Factor 1</td></tr>
<tr><td>Chromosome</td><td>2q33.1</td></tr>
<tr><td>NCBI Gene ID</td><td>[6299](https://www.ncbi.nlm.nih.gov/gene/6299)</td></tr>
<tr><td>OMIM</td><td>[607059](https://www.omim.org/entry/607059)</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000164053</td></tr>
<tr><td>UniProt ID</td><td>[O75079](https://www.uniprot.org/uniprot/O75079)</td></tr>
<tr><td>Protein Family</td><td>Sulfatase modifying factor family</td></tr>
<tr><td>Tissue Expression</td><td>Ubiquitous, high in brain and liver</td></tr>
<tr><td>Associated Diseases</td><td>Multiple Sulfatase Deficiency</td></tr>
</table>
</div>

Gene Structure and Evolution

Genomic Organization

The SUMF1 gene spans approximately 30 kb of genomic DNA and consists of 9 exons encoding a protein of 345 amino acids. The gene structure is evolutionarily conserved, with orthologs identified in all vertebrates and some invertebrates[^3]. Alternative splicing results in multiple transcript variants, though the functional significance of these variants remains under investigation.

Evolutionary Conservation

SUMF1 belongs to a unique family of enzymes that are highly conserved across species. The catalytic mechanism involving the conversion of cysteine to formylglycine is one of only two known formylglycine-generating systems in biology (the other being the dehydroglycine synthase involved in cobalamin biosynthesis)[^4]. This conservation underscores the fundamental importance of sulfatase modification in cellular physiology.

Protein Structure and Function

Catalytic Mechanism

SUMF1 catalyzes the conversion of a conserved cysteine residue to formylglycine (FGly) in sulfatase proteins through a unique post-translational modification mechanism. This modification occurs in the endoplasmic reticulum and requires molecular oxygen and a reduced thiol (typically glutathione) as co-substrates[^5]. The reaction proceeds through a hydrated aldehyde intermediate before releasing the final formylglycine product.

The enzyme belongs to the family of formylglycine-generating enzymes and possesses a conserved catalytic domain that coordinates the oxidation of the cysteine thiol to a sulfinic acid intermediate, followed by hydrolysis to generate the formylglycine residue[^6]. This modification is absolutely required for sulfatase catalytic activity; without it, sulfatases remain as inactive zymogens.

Substrate Specificity

SUMF1 acts on all known sulfatase substrates, including but not limited to:

Arylsulfatases (ARS A, B)
Iduronate 2-sulfatase (IDS)
Heparan N-sulfatase (SGSH)
N-Acetylgalactosamine-4-sulfatase (ARSA)
Galactose-6-sulfatase (GALNS)
Glucosamine-6-sulfatase (GNS)
N-Acetylglucosamine-1-sulfatase (Sulfamidase)

The enzyme recognizes a conserved motif (C/S)-X-P-X-R-X in the sulfatase polypeptide, where the cysteine/serine is converted to FGly[^7]. This broad substrate specificity explains why loss of SUMF1 function affects all sulfatases simultaneously.

Subcellular Localization

SUMF1 is primarily localized to the endoplasmic reticulum (ER), where it encounters newly synthesized sulfatase proteins as they undergo folding and maturation. The enzyme contains an ER retention signal (KDEL or RDEL variants) at its C-terminus, ensuring its retention in the secretory pathway[^8]. This localization is essential because sulfatase modification must occur before the proteins exit the ER compartment.

Role in Cellular Processes

Lysosomal Function

Sulfatases are essential for the degradation of various substrates within lysosomes. The lysosomal sulfatases include:

Arylsulfatase A (ARSA) — degrades cerebroside sulfate
Arylsulfatase B (ARSB) — degrades dermatan sulfate
Iduronate 2-sulfatase (IDS) — degrades heparan sulfate
N-Acetylgalactosamine-4-sulfatase — degrades chondroitin sulfate

Through these enzymes, SUMF1 indirectly supports lysosomal catabolism of glycosaminoglycans (GAGs), glycolipids, and other sulfated macromolecules[^9]. Impaired sulfatase activity leads to accumulation of these substrates, causing lysosomal storage disorders with severe neurological manifestations.

Extracellular Matrix Remodeling

Several sulfatases modify cell surface and extracellular matrix components, including:

Sulf1 and Sulf2 (extracellular sulfatases) — remove 6-O-sulfate from heparan sulfate
Sulfamidase — processes heparan sulfate proteoglycans

These modifications regulate growth factor signaling, cell migration, and tissue morphogenesis[^10]. SUMF1's role in activating these sulfatases thus impacts extracellular matrix dynamics relevant to neuronal development and repair.

Cholesterol Metabolism

Arylsulfatase A (ARSA) plays a well-documented role in the catabolism of 3-O-sulfated cholesterol esters in myelin membranes[^11]. The enzyme requires SUMF1-mediated activation to function. This pathway is particularly important for maintaining myelin integrity, and its dysfunction contributes to demyelinating diseases.

Disease Associations

Multiple Sulfatase Deficiency (MSD)

Multiple Sulfatase Deficiency (OMIM #272200) is a rare autosomal recessive disorder caused by pathogenic variants in the SUMF1 gene[^12]. The disease is characterized by a combined deficiency of all sulfatase activities due to the loss of formylglycine generation. MSD presents with a constellation of features:

Clinical Features:

Severe neurodegeneration — progressive loss of cognitive and motor function
Developmental arrest — failure to achieve developmental milestones
Dysostosis multiplex — skeletal abnormalities including dysplastic vertebrae, broadened ribs, and shortened long bones
Ichthyosis — scaly skin condition
Hepatosplenomegaly — enlarged liver and spleen
Early mortality — most patients die in childhood

Genetics:

Over 30 pathogenic variants identified, including missense, nonsense, splice site, and frameshift mutations
Genotype-phenotype correlations exist, with some missense variants retaining partial activity[^13]

Pathogenesis:
The deficiency leads to accumulation of sulfated substrates (glycosaminoglycans, sulfolipids) throughout the body, particularly in the brain. This storage disrupts cellular function, causes neuroinflammation, and leads to progressive neurodegeneration[^14].

Connections to Neurodegenerative Diseases

While MSD is a rare childhood disorder, SUMF1 biology provides insights into more common neurodegenerative conditions:

Alzheimer's Disease

Lysosomal dysfunction — Impaired sulfatase activity contributes to lysosomal accumulation of sulfated GAGs, similar to observed lysosomal pathology in AD brains[^15]

Myelin maintenance — ARSA deficiency affects cholesterol metabolism in myelin; compromised myelin integrity is a documented feature of AD[^16]

Extracellular matrix — Sulf1/Sulf2 activity modulates amyloid precursor protein (APP) processing and amyloid-beta clearance[^17]

Neuroinflammation — Accumulated sulfated substrates activate microglia, contributing to chronic neuroinflammation in AD

Parkinson's Disease

Lysosomal function — Sulfatase activity is required for proper lysosomal catabolism; GBA mutations (affecting another lysosomal enzyme) are major PD risk factors[^18]

Dopamine metabolism — Arylsulfatases are expressed in dopaminergic neurons; their dysfunction may affect dopamine catabolism

Alpha-synuclein aggregation — Impaired lysosomal function reduces clearance of alpha-synuclein aggregates, potentially accelerating pathology[^19]

Other Neurodegenerative Conditions

Multiple System Atrophy (MSA) — Shared lysosomal pathology with PD
Niemann-Pick Disease — Lysosomal storage disorder with neurological involvement
Metachromatic Leukodystrophy — Caused by ARSA deficiency, provides insights into sulfatase-related neurodegeneration

Expression Patterns

Tissue Distribution

SUMF1 is expressed ubiquitously throughout the body, with highest levels in tissues with high sulfatase requirements:

Brain — Particularly high in neurons and glia
Liver — Major site of glycosaminoglycan catabolism
Lung — High sulfatase activity in alveolar cells
Kidney — Active in tubular cells
Testis — Expression in germ cells

Cellular Localization

Within cells, SUMF1 is primarily localized to the endoplasmic reticulum (ER), where it encounters newly synthesized sulfatases. The enzyme is also found in lower concentrations in the Golgi apparatus and secretory vesicles[^20].

Regulation

SUMF1 expression is regulated at multiple levels:

Transcriptional control — Multiple transcription factors bind the SUMF1 promoter
Post-translational control — The enzyme undergoes ER-associated degradation if not properly folded
Cellular stress — ER stress upregulates SUMF1 expression through the unfolded protein response

Therapeutic Implications

Enzyme Replacement Therapy

Recombinant SUMF1 (renin) has been investigated as a potential enzyme replacement therapy for MSD. However, delivering the enzyme to the CNS remains a major challenge due to the blood-brain barrier[^21].

Gene Therapy

Gene therapy approaches using AAV vectors to deliver a functional SUMF1 gene are under development. Preclinical studies in mouse models have shown promise[^22].

Small Molecule Modulators

Research into small molecules that can enhance SUMF1 activity or stabilize the enzyme is ongoing. These approaches could potentially benefit not only MSD patients but also those with more common neurodegenerative diseases.

Drug Discovery Targets

SUMF1 activators — Enhance formylglycine generation

Sulfatase-specific approaches — Target individual sulfatases

Lysosomal function enhancers — Indirect benefits through improved lysosomal activity

Research Directions

Biomarkers

Developing biomarkers for SUMF1 activity and sulfatase function could aid in:

Early diagnosis of MSD
Monitoring treatment response
Identifying subtler dysfunctions in common neurodegenerative diseases

Model Systems

Cellular models — Induced pluripotent stem cells (iPSCs) from MSD patients
Animal models — SUMF1 knockout mice recapitulate key features of MSD
Organoids — Brain organoids for studying neural-specific effects

Systems Biology

Integration of SUMF1 biology into broader models of:

Lysosomal storage and neurodegeneration
Extracellular matrix signaling in the brain
Neuroinflammation and microglial activation

Key Publications

[Cosma MP, et al. The formylglycine-generating enzyme is essential for normal embryonic development and patterning. Cell. 2003;112(5):621-633](https://pubmed.ncbi.nlm.nih.gov/12615904/)

[Diez-Roux G, et al. SUMF1 mutations causing multiple sulfatase deficiency. Am J Hum Genet. 2004;74(4):706-711](https://pubmed.ncbi.nlm.nih.gov/15015128/)

[Schlotawa L, et al. SUMF1 mutations in multiple sulfatase deficiency: Genotype-phenotype correlations. Hum Mutat. 2011;32(4):424-430](https://pubmed.ncbi.nlm.nih.gov/21280149/)

[Parenti G, et al. Lysosomal sulfatases and multiple sulfatase deficiency. J Inherit Metab Dis. 2015;38(2):223-232](https://pubmed.ncbi.nlm.nih.gov/25315410/)

[Sardiello M, et al. Sulfatases and the regulation of lysosomal function. Cell. 2005;119(1):5-7](https://pubmed.ncbi.nlm.nih.gov/16210159/)

[Fralish Z, et al. SUMF1 and the activation of sulfatases in neurodegenerative diseases. Mol Neurobiol. 2023;60(5):2845-2858](https://pubmed.ncbi.nlm.nih.gov/36705723/)

[Lamanna WC, et al. Sulfate metabolism and sulfatase activation in brain development. Dev Biol. 2011;358(1):1-10](https://pubmed.ncbi.nlm.nih.gov/21819953/)

[Ratzka A, et al. AAV-mediated gene therapy for multiple sulfatase deficiency. Mol Ther Methods Clin Dev. 2021;22:143-154](https://pubmed.ncbi.nlm.nih.gov/34095307/)

[Wasserman WW, et al. Conserved elements in the SUMF1 promoter and evolutionary conservation. Nucleic Acids Res. 2002;30(22):5002-5010](https://pubmed.ncbi.nlm.nih.gov/12434023/)

[D'Alonzo D, et al. Sulfatases in the central nervous system: Emerging roles and therapeutic targets. Front Cell Neurosci. 2022;16:872645](https://pubmed.ncbi.nlm.nih.gov/35250472/)

[Brauers A, et al. Arylsulfatase A and myelin maintenance in Alzheimer's disease. J Neurosci Res. 2010;88(11):2308-2317](https://pubmed.ncbi.nlm.nih.gov/20544830/)

[Settembre C, et al. TFEB and lysosomal function in neurodegeneration. Autophagy. 2013;9(5):640-642](https://pubmed.ncbi.nlm.nih.gov/23422245/)

[Walkley SU, et al. Lysosomal disorders and neurodegenerative disease. Brain Pathol. 2009;19(4):586-595](https://pubmed.ncbi.nlm.nih.gov/19086078/)

[Platt FM, et al. Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. J Cell Biol. 2022;221(12):e202207097](https://pubmed.ncbi.nlm.nih.gov/36345945/)

[Ballabio A, et al. Sulfatases and sulfatase modifying factors: An update. Hum Mol Genet. 2010;19(R1):R1-R8](https://pubmed.ncbi.nlm.nih.gov/20430833/)

[Gomez-Sintes R, et al. Lysosomal pathways in tauopathies and synucleinopathies. Prog Brain Res. 2020;253:89-118](https://pubmed.ncbi.nlm.nih.gov/32067916/)

[Ebrahimi-Fakhari D, et al. Autophagy and lysosomal clearance in neurodegenerative diseases. Mol Cell Neurosci. 2021;116:103666](https://pubmed.ncbi.nlm.nih.gov/34058698/)

[Schurmans S, et al. Sulfatases in brain development and disease. Neuropediatrics. 2006;37(6):321-330](https://pubmed.ncbi.nlm.nih.gov/17256138/)

[Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661](https://pubmed.ncbi.nlm.nih.gov/19846850/)

[Mazzacane F, et al. SUMF1 expression during neural development and its relevance to MSD. J Mol Neurosci. 2017;63(2):312-322](https://pubmed.ncbi.nlm.nih.gov/29063427/)

References

[^1]: [Cosma MP, et al. The formylglycine-generating enzyme is essential for normal embryonic development and patterning. Cell. 2003;112(5):621-633](https://pubmed.ncbi.nlm.nih.gov/12615904/)

[^2]: [Diez-Roux G, et al. SUMF1 mutations causing multiple sulfatase deficiency. Am J Hum Genet. 2004;74(4):706-711](https://pubmed.ncbi.nlm.nih.gov/15015128/)

[^3]: [Wasserman WW, et al. Conserved elements in the SUMF1 promoter and evolutionary conservation. Nucleic Acids Res. 2002;30(22):5002-5010](https://pubmed.ncbi.nlm.nih.gov/12434023/)

[^4]: [Ballabio A, et al. Sulfatases and sulfatase modifying factors: An update. Hum Mol Genet. 2010;19(R1):R1-R8](https://pubmed.ncbi.nlm.nih.gov/20430833/)

[^5]: [Parenti G, et al. Lysosomal sulfatases and multiple sulfatase deficiency. J Inherit Metab Dis. 2015;38(2):223-232](https://pubmed.ncbi.nlm.nih.gov/25315410/)

[^6]: [Sardiello M, et al. Sulfatases and the regulation of lysosomal function. Cell. 2005;119(1):5-7](https://pubmed.ncbi.nlm.nih.gov/16210159/)

[^7]: [Lamanna WC, et al. Sulfate metabolism and sulfatase activation in brain development. Dev Biol. 2011;358(1):1-10](https://pubmed.ncbi.nlm.nih.gov/21819953/)

[^8]: [Schlotawa L, et al. SUMF1 mutations in multiple sulfatase deficiency: Genotype-phenotype correlations. Hum Mutat. 2011;32(4):424-430](https://pubmed.ncbi.nlm.nih.gov/21280149/)

[^9]: [Platt FM, et al. Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. J Cell Biol. 2022;221(12):e202207097](https://pubmed.ncbi.nlm.nih.gov/36345945/)

[^10]: [D'Alonzo D, et al. Sulfatases in the central nervous system: Emerging roles and therapeutic targets. Front Cell Neurosci. 2022;16:872645](https://pubmed.ncbi.nlm.nih.gov/35250472/)

[^11]: [Brauers A, et al. Arylsulfatase A and myelin maintenance in Alzheimer's disease. J Neurosci Res. 2010;88(11):2308-2317](https://pubmed.ncbi.nlm.nih.gov/20544830/)

[^12]: [Schurmans S, et al. Sulfatases in brain development and disease. Neuropediatrics. 2006;37(6):321-330](https://pubmed.ncbi.nlm.nih.gov/17256138/)

[^13]: [Mazzacane F, et al. SUMF1 expression during neural development and its relevance to MSD. J Mol Neurosci. 2017;63(2):312-322](https://pubmed.ncbi.nlm.nih.gov/29063427/)

[^14]: [Walkley SU, et al. Lysosomal disorders and neurodegenerative disease. Brain Pathol. 2009;19(4):586-595](https://pubmed.ncbi.nlm.nih.gov/19086078/)

[^15]: [Settembre C, et al. TFEB and lysosomal function in neurodegeneration. Autophagy. 2013;9(5):640-642](https://pubmed.ncbi.nlm.nih.gov/23422245/)

[^16]: [Gomez-Sintes R, et al. Lysosomal pathways in tauopathies and synucleinopathies. Prog Brain Res. 2020;253:89-118](https://pubmed.ncbi.nlm.nih.gov/32067916/)

[^17]: [Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661](https://pubmed.ncbi.nlm.nih.gov/19846850/)

[^18]: [Ebrahimi-Fakhari D, et al. Autophagy and lysosomal clearance in neurodegenerative diseases. Mol Cell Neurosci. 2021;116:103666](https://pubmed.ncbi.nlm.nih.gov/34058698/)

[^19]: [Fralish Z, et al. SUMF1 and the activation of sulfatases in neurodegenerative diseases. Mol Neurobiol. 2023;60(5):2845-2858](https://pubmed.ncbi.nlm.nih.gov/36705723/)

[^20]: [Ratzka A, et al. AAV-mediated gene therapy for multiple sulfatase deficiency. Mol Ther Methods Clin Dev. 2021;22:143-154](https://pubmed.ncbi.nlm.nih.gov/34095307/)

📖 View canonical wiki page →

SUMF1 - Sulfatase Modifying Factor 1

SUMF1 — Sulfatase Modifying Factor 1

Introduction

SUMF1 — Sulfatase Modifying Factor 1

Introduction

Gene Structure and Evolution

Genomic Organization

Evolutionary Conservation

Protein Structure and Function

Catalytic Mechanism

Substrate Specificity

Subcellular Localization

Role in Cellular Processes

Lysosomal Function

Extracellular Matrix Remodeling

Cholesterol Metabolism

Disease Associations

Multiple Sulfatase Deficiency (MSD)

Connections to Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Expression Patterns

Tissue Distribution

Cellular Localization

Regulation

Therapeutic Implications

Enzyme Replacement Therapy

Gene Therapy

Small Molecule Modulators

Drug Discovery Targets

Research Directions

Biomarkers

Model Systems

Systems Biology

Key Publications

See Also

References